| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Novartis receives an exclusive license to an undisclosed discovery target
Novartis also receives options to license two programs from Monte Rosa's growing preclinical immunology portfolio
Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales
Extended cash runway enables Monte Rosa to accelerate preclinical and clinical-stage immunology & inflammation (I&I) pipeline
BOSTON, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced an agreement to collaborate with Novartis to develop novel degraders for immune-mediated diseases. The agreement is the Company's second with Novartis, in addition to the global exclusive license agreement for Monte Rosa's VAV1 degraders including MRT-6160, announced in October 2024.
The agreement announced today was uniquely structured by the companies to collaborate on accelerating development of degraders for important immune-mediated diseases driven by highly credentialed and difficult-to-drug targets. Under the agreement, Monte Rosa's scientists will apply their proprietary AI/ML-enabled QuEEN™ product engine for the discovery and development of degraders to be further developed and commercialized by Novartis.
Agreement Details and Financial Terms Under the terms of the agreement, Monte Rosa will receive an upfront payment of $120 million. Monte Rosa will also receive payments to maintain the options. In total deal value, Monte Rosa is eligible to receive up to $5.7 billion, including upfront, option maintenance, preclinical milestone, option exercise, and development, regulatory, and sales milestone payments across programs, as well as tiered royalties on global net sales in the high single to low double-digit range. Monte Rosa's publicly disclosed pipeline programs are outside the scope of this agreement. Monte Rosa plans to provide further information regarding its updated cash position and runway in its third quarter 2025 earnings update.Posted In: GLUE
